CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion (Q24634660)

1

0 references

L S Cox

2

0 references

N Nollen

3

0 references

B Faseru

4

0 references

K S Okuyemi

5

0 references

J S Ahluwalia

6

0 references

N L Benowitz

Clinical Pharmacology & Therapeutics

7

0 references

language of work or name

English

0 references

publication date

December 2012

0 references

published in

0 references

volume

92

0 references

issue

6

0 references

page(s)

771-7

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Behavioral and biochemical investigations of bupropion metabolites

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Bupropion for smoking cessation in African American light smokers: a randomized controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Non-nicotinic therapies for smoking cessation.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation

27 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

27 September 2017

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Clinical pharmacokinetics of bupropion: a review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3729209

The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design

30 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Disparities in smoking cessation between African Americans and Whites: 1990-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Relationship between menthol cigarettes and smoking cessation among African American light smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Predictors of smoking cessation among African-Americans enrolled in a randomized controlled trial of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.186

Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23149928

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Stability of bupropion and its major metabolites in human plasma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23149928

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23149928